SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies ...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for ...
While a cure remains elusive, cancer treatment has seen significant advances in recent years. New innovations include ...
Distinct outcomes with the detection of endemic Burkitt lymphoma, T-cell receptor (TCR) complementarity determining region-3s (CDR3s) matching known anti-HIV TCR CDR3s. This is an ASCO Meeting ...
SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...
In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...
Morning Overview on MSN
Scientists finally crack why some cancer treatments suddenly stop working
After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in patients on immunotherapy and targeted drugs: a dramatic initial response, then ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results